Literature DB >> 26091280

Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013.

T Forrester1, D Siskind2, K Winckel1, A Wheeler3, S Hollingworth4.   

Abstract

INTRODUCTION: Clozapine is the most effective treatment for treatment-resistant schizophrenia but its use is suboptimal.
METHODS: Clozapine dispensing data from Queensland, Australia were extracted (2004-2013). The number of people dispensed clozapine each year and mean maintenance doses were calculated. The 18-week and 5-year cessation and treatment interruption rates were calculated using Kaplan-Meier analysis.
RESULTS: Clozapine dispensings increased 36.4% (p<0.001) from 44 to 60 people per 100,000. This was estimated as 8.3% of people with schizophrenia and 33.3% of people with treatment resistant schizophrenia dispensed clozapine in 2013. Mean maintenance dose did not significantly change (364-399 mg) over 5 years of treatment. One in 7 (14.2%) people ceased within the first 3 weeks. 3-quarters (72.7%) reached maintenance therapy. The 5-year actuarial estimate of the proportion of people a) dispensed clozapine was 0.610 (S.E. 0.011) and b) with an interruption to treatment was 0.422 (S.E. 0.013). DISCUSSION: The number of patients being dispensed clozapine increased between 2004 and 2013 but clozapine is still underused. Increased use combined with continued monitoring for adverse effects will improve quality use of clozapine. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26091280     DOI: 10.1055/s-0035-1554713

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  11 in total

Review 1.  Clozapine in primary care.

Authors:  Karl Winckel; Dan Siskind
Journal:  Aust Prescr       Date:  2017-12-04

Review 2.  Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.

Authors:  Dan Siskind; Victor Siskind; Steve Kisely
Journal:  Can J Psychiatry       Date:  2017-06-28       Impact factor: 4.356

3.  Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014.

Authors:  Samantha A Hollingworth; Karl Winckel; Nargess Saiepour; Amanda J Wheeler; Nicholas Myles; Dan Siskind
Journal:  Psychopharmacology (Berl)       Date:  2018-03-27       Impact factor: 4.530

4.  Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.

Authors:  D J Siskind; M Harris; A Phillipou; V A Morgan; A Waterreus; C Galletly; V J Carr; C Harvey; D Castle
Journal:  Epidemiol Psychiatr Sci       Date:  2016-07-18       Impact factor: 6.892

5.  The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study.

Authors:  D Siskind; T Reddel; J H MacCabe; S Kisely
Journal:  Psychopharmacology (Berl)       Date:  2019-02-04       Impact factor: 4.530

Review 6.  Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement.

Authors:  Nilamadhab Kar; Socorro Barreto; Rahul Chandavarkar
Journal:  Clin Psychopharmacol Neurosci       Date:  2016-11-30       Impact factor: 2.582

7.  Antipsychotic prescribing for vulnerable populations: a clinical audit at an acute Australian mental health unit at two-time points.

Authors:  Sara S McMillan; Sara Jacobs; Louise Wilson; Theo Theodoros; Gail Robinson; Claire Anderson; Gabor Mihala; Amanda J Wheeler
Journal:  BMC Psychiatry       Date:  2017-04-13       Impact factor: 3.630

8.  CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.

Authors:  Dan Siskind; Nadia Friend; Anthony Russell; John J McGrath; Carmen Lim; Sue Patterson; Dylan Flaws; Terry Stedman; Vikas Moudgil; Savio Sardinha; Shuichi Suetani; Steve Kisely; Karl Winckel; Andrea Baker
Journal:  BMJ Open       Date:  2018-03-02       Impact factor: 2.692

9.  Implementing a clozapine supply service in Australian community pharmacies: barriers and facilitators.

Authors:  Bethany Wilson; Sara S McMillan; Amanda J Wheeler
Journal:  J Pharm Policy Pract       Date:  2019-08-07

Review 10.  Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.

Authors:  Ana Miruna Dragoi; Ioana Radulescu; Bogdana Adriana Năsui; Anca Lucia Pop; Valentin Nicolae Varlas; Simona Trifu
Journal:  Brain Sci       Date:  2020-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.